The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression
Top Cited Papers
- 16 December 2008
- journal article
- review article
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 24 (1) , 27-53
Abstract
Despite extensive research, the current theories on serotonergic dysfunctions and cortisol hypersecretion do not provide sufficient explanations for the nature of depression. Rational treatments aimed at causal factors of depression are not available yet. With the currently available antidepressant drugs, which mainly target serotonin, less than two thirds of depressed patients achieve remission. There is now evidence that inflammatory and neurodegenerative (I&ND) processes play an important role in depression and that enhanced neurodegeneration in depression may–at least partly–be caused by inflammatory processes. Multiple inflammatory-cytokines, oxygen radical damage, tryptophan catabolites–and neurodegenerative biomarkers have been established in patients with depression and these findings are corroborated by animal models of depression. A number of vulnerability factors may predispose towards depression by enhancing inflammatory reactions, e.g. lower peptidase activities (dipeptidyl-peptidase IV, DPP IV), lower omega-3 polyunsaturated levels and an increased gut permeability (leaky gut). The cytokine hypothesis considers that external, e.g. psychosocial stressors, and internal stressors, e.g. organic inflammatory disorders or conditions, such as the postpartum period, may trigger depression via inflammatory processes. Most if not all antidepressants have specific anti-inflammatory effects, while restoration of decreased neurogenesis, which may be induced by inflammatory processes, may be related to the therapeutic efficacy of antidepressant treatments. Future research to disentangle the complex etiology of depression calls for a powerful paradigm shift, i.e. by means of a high throughput-high quality screening, including functional genetics and genotyping microarrays; established and novel animal and ex vivo–in vitro models for depression, such as new transgenic mouse models and endophenotype-based animal models, specific cell lines, in vivo and ex vivo electroporation, and organotypic brain slice culture models. This screening will allow to: 1) discover new I&ND biomarkers, both at the level of gene expression and the phenotype; and elucidate the underlying molecular I&ND pathways causing depression; and 2) identify new therapeutic targets in the I&ND pathways; develop new anti-I&ND drugs for these targets; select existing anti-I&ND drugs or substances that could augment the efficacy of antidepressants; and predict therapeutic response by genetic I&ND profiles.Keywords
This publication has 188 references indexed in Scilit:
- Tryptophan breakdown pathway in bipolar maniaJournal of Affective Disorders, 2007
- Social isolation increases number of newly proliferated cells in hippocampus in female flinders sensitive line ratsHippocampus, 2007
- Omega-3 fatty acids upregulate adult neurogenesisNeuroscience Letters, 2007
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- Depression: a case of neuronal life and death?Biological Psychiatry, 2004
- Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimeticsExpert Opinion on Biological Therapy, 2003
- Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-β through AP-1-mediated transcriptional repressionThe International Journal of Biochemistry & Cell Biology, 2002
- Developmental Regulation of BDNF and NT-3 Expression by Quinolinic Acid in the Striatum and Its Main ConnectionsExperimental Neurology, 2000
- Α Review on the Acute Phase Response in Major DepressionReviews in the Neurosciences, 1993
- Differential vulnerability of central neurons of the rat to quinolinic acidNeuroscience Letters, 1983